Today, The Home Depot, Inc. (NYSE: HD) will be holding its 2023 Investor and Analyst Conference to discuss its strategic priorities focused on delivering the best customer experience in the home improvement sector.

As the conference approaches, The Home Depot has reaffirmed its fiscal 2023 guidance, anticipating -among other things-, a decline in sales and comparable sales of 2% to 5% compared to the previous year and a decline in diluted earnings-per-share of 7% to 13% compared to fiscal 2022. 

In pre-market, $HD is currently trading at $303.57, reflecting a positive increase of $2.71 (+0.90%).

Ocular Therapeutix, Inc.? (Nasdaq: OCUL), a biopharmaceutical company specializing in the development and commercialization of innovative therapies for eye diseases, has seen its price target raised from $10 to $12 by HC Wainwright & Co. 

With $OCUL closing at $6.50 on Monday, this revised price target suggests a potential upside of $5.50 or 84.62%, as per the investment firm's view.

Yesterday, HC Wainwright & Co. initiated coverage on Oculis Holding AG (Nasdaq: OCS), a pharmaceutical company focused on developing innovative ophthalmic treatments, with a Buy rating and a price target of $28. 

Based on Monday's closing price of $11.57, the price target implies a potential upside of $16.43 or 141.99% for $OCS, according to the financial services firm's analysis.

These potential upsides represent projections based on the views and assessments of HC Wainwright & Co., taking into account various factors and market conditions. Investors should exercise caution and conduct their own analysis before making any investment decisions.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)